KORU Medical Systems (NASDAQ:KRMD) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

KORU Medical Systems (NASDAQ:KRMD) posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01, Zacks reports. The company had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $10.90 million. KORU Medical Systems had a negative return on equity of 15.90% and a negative net margin of 6.41%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• CEO Linda Tharby announced her planned retirement effective June 30, 2026, with CCO Adam Kalbermatten named President on March 15 and set to become CEO on July 1, and Linda remaining as an advisor through year-end.
• KORU delivered strong financials with Q4 revenue of $10.9M (+23% YoY), full-year revenue of $41.1M (+22%), positive adjusted EBITDA (~$0.6M) and positive operating cash flow, ending 2025 with $8.9M cash.
• International momentum accelerated (Q4 international growth ~71%, full-year ~80%), and EU MDR clearance for the Freedom60 prefilled-syringe compatibility enables shipments into Europe and targets an estimated $50M addressable market.
• KORU is expanding beyond IG — received 510(k) clearance for RYSTIGGO (entry into infusion clinics), has 9 drugs on label and 9 active pipeline collaborations (including near-term vancomycin, deferoxamine, Phesgo), and guided 2026 revenue of $47.5–$50M with positive adjusted EBITDA and full-year positive cash flow.
• Headwinds include modest gross margin pressure from higher material costs, tariffs and geographic mix, a 30% decline in PST (pharma services & trials) revenue due to milestone timing, and a relatively modest year-end cash balance that could leave limited downside cushion if expected milestones or prefill conversions slip.

KORU Medical Systems Price Performance

NASDAQ:KRMD remained flat at $4.32 during trading hours on Friday. The company had a trading volume of 53,642 shares, compared to its average volume of 154,533. The company has a market cap of $200.32 million, a PE ratio of -72.00 and a beta of 0.55. KORU Medical Systems has a twelve month low of $1.86 and a twelve month high of $6.61. The business’s 50 day moving average is $4.73 and its two-hundred day moving average is $4.81.

Hedge Funds Weigh In On KORU Medical Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Lazard Asset Management LLC bought a new position in KORU Medical Systems during the 2nd quarter worth approximately $59,000. Occudo Quantitative Strategies LP bought a new stake in shares of KORU Medical Systems in the 4th quarter valued at $127,000. Cubist Systematic Strategies LLC boosted its stake in shares of KORU Medical Systems by 927.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock valued at $196,000 after purchasing an additional 69,758 shares during the last quarter. Geode Capital Management LLC increased its position in shares of KORU Medical Systems by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock worth $5,944,000 after buying an additional 16,062 shares during the period. Finally, State Street Corp raised its stake in KORU Medical Systems by 32.6% during the fourth quarter. State Street Corp now owns 602,645 shares of the company’s stock worth $3,501,000 after buying an additional 148,166 shares during the last quarter. 58.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Lake Street Capital upped their price objective on shares of KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. B. Riley Financial boosted their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Craig Hallum reiterated a “buy” rating and issued a $7.00 price target on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Canaccord Genuity Group reissued a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a report on Friday, March 13th. Finally, Wall Street Zen cut KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.